BIONOR PHARMA ASA
STOCK EXCHANGE ANNOUNCEMENT
Dr. Brian G. Gazzard and Dr. Robert Redfield have stepped down from the Clinical Advisory Board.
Following these changes, the Clinical Advisory Board of Bionor now comprises:
New Clinical Advisory Board member biographies:
Steven G. Deeks, M.D.
Steven G. Deeks, M.D. is Professor of Medicine in Residence at the University of California, San Francisco and a faculty member in the Positive Health Program (AIDS Program) at San Francisco General Hospital. Dr. Deeks has been engaged in HIV research and clinical care since 1993. He is an expert on the role of chronic inflammation in untreated and treated HIV disease. His research has several linked objectives, including "persistent inflammation during therapy, novel therapeutic interventions to reduce chronic inflammation and the size of the latent reservoir". Dr. Deeks has published over 300 peer-review articles, editorials and invited reviews. He is the principle investigator of NIH-funded international collaboration aimed at developing therapeutic interventions to cure HIV infection (DARE). Dr. Deeks is the co-chair of the "Towards an HIV Cure" International Working Group and member of the Office of AIDS Research Advisory Council (ORAC). He is a member of the Department on Health and Human Services Panel on Antiretroviral Guidelines. In addition to research, Dr. Deeks maintains a primary care clinic for HIV infected patients.
Christine Katlama, M.D.
Christine Katlama, M.D. is Professor of Infectious Diseases at Pierre and Marie Curie University in Paris. She is head of the AIDS clinical care unit at Pitié Salpetriere Hospital and co-director of the HIV clinical epidemiology unit at Pierre Louis Institute Paris Sorbonne. Professor Katlama is also actively involved in the ANRS (French National Agency for HIV Research) and heads its antiretroviral strategy group. She cofunded the ORVVACS network towards HIV vaccine and Cure. Christine Katlama has worked with HIV since 1982 and was involved in the HIV-2 discovery in 1986. Her group first demonstrated the impact of HAART on immune reconstitution and works extensively in the field of new drugs, viral resistance, novel antiretroviral strategies and HIV cure. Christine Katlama is actively involved in the NEAT European Network and since 2011, in the IAS HIV cure initiative. Professor Katlama is a past President of EACS and is currently in charge of the EACS educational programme, organizing the EACS Advanced HIV Course and the ECRECO Clinical Research Course. She is a member of numerous international HIV advisory boards for pharmaceutical companies and is on the editorial boards of several journals, including HIV Medicine and AIDS, with over 400 articles on HIV clinical science to her name.
Daniel Kuritzkes, M.D.
Daniel Kuritzkes, M.D. is Professor of Medicine at Harvard Medical School and Division Chief at an affiliated academic teaching hospital. He received his B.S. and M.S. degrees from Yale University and his M.D. from Harvard Medical School. Dr. Kuritzkes has published more than 300 research articles, reviews and book chapters. He is a member of the U.S. Department of Health and Human Services panel on guidelines for antiretroviral therapy, has served on NIH editorial boards and committees, and previously served as Chair of the HIV Medicine Association Board of Directors. Dr. Kuritzkes has chaired several multicenter HIV studies, and he currently serves as Principal Investigator and Chair of the AIDS Clinical Trials Group. Dr. Kuritzkes is an Associate Editor of the Journal of Infectious Diseases. His research interests focus on resistance to antiretroviral drugs, viral fitness, viral tropism, HIV-1 persistence and eradication.
David H. Solomon, President and CEO, +45 22 20 63 00, firstname.lastname@example.org
Jørgen F. Ravn, VP Investor Relations & Communications, +45 20 30 39 03, email@example.com
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a possible functional HIV cure. The Company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. Bionor is currently well advanced in the planning of BIOSKILL, a proof-of-concept Phase II clinical, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights of Vacc-4x, i.e., the upside potential from partnering or licensing remain with the Company's shareholders. Bionor Pharma is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York City, New York. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com .
Last updated on: 30/10/2015
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.